Literature DB >> 7741036

Interactions of P 1507, a new antioxidant agent, with phagocyte functions.

F Meloni1, P Ballabio, G Leo, M Gorrini, S Manzardo, G Coppi, M Luisetti.   

Abstract

Toxic oxygen free radicals are believed to play a role in the pathogenesis of a number of respiratory diseases. In particular, pulmonary emphysema may occur because of the oxidative impairment of alpha 1-proteinase inhibitor (alpha 1-PI). We report in vitro data on a new thiol agent, P 1507 [N-5-(thioxo-L-prolyl)-L-cysteine], obtained in a series of experiments designed in view of its therapeutic potential in these clinical conditions. We found that P 1507 at the concentration of 5 x 10(-6) M was able to almost fully abolish the PMA-triggered PMN-induced oxidative impairment of alpha 1-PI. Protection may be due to the radical scavenger ability of P 1507, that markedly reduced superoxide anion production from PMNs. We also found that P 1507 did not significantly impair other defence mechanisms of PMNs (i.e. phagocytosis, chemotaxis and bactericidal activity). The release of cytokines (TNF-alpha, IL-6 and IL-8) from monocytes was not altered in the presence of P 1507. We conclude that the compound P 1507 may be considered for treatment of clinical conditions characterized by overload of oxidants, on the basis of its ability in preventing the oxidative damage of alpha 1-PI and of a lack of unwanted inhibitory effects towards defence mechanisms of phagocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7741036     DOI: 10.1007/BF02005759

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  18 in total

1.  Regulation of the acute phase and immune responses: interleukin-6.

Authors: 
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

2.  Inhibition of neutrophil elastase by alpha-1-proteinase inhibitor oxidized by activated neutrophils.

Authors:  M Padrines; M Schneider-Pozzer; J G Bieth
Journal:  Am Rev Respir Dis       Date:  1989-03

3.  The oxidative inactivation of human alpha-1-proteinase inhibitor. Further evidence for methionine at the reactive center.

Authors:  D Johnson; J Travis
Journal:  J Biol Chem       Date:  1979-05-25       Impact factor: 5.157

Review 4.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

5.  Search for drugs that may reduce the load of neutrophil azurophilic granule enzymes in the lungs of patients with emphysema.

Authors:  M D Stevens; E J Miller; A B Cohen
Journal:  Exp Lung Res       Date:  1989-07       Impact factor: 2.459

6.  Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases.

Authors:  J B Richman-Eisenstat; P G Jorens; C A Hébert; I Ueki; J A Nadel
Journal:  Am J Physiol       Date:  1993-04

7.  Inactivation of alpha 1-proteinase inhibitor by alveolar inflammatory cells from smoking patients with or without emphysema.

Authors:  B Wallaert; B Gressier; C H Marquette; P Gosset; M Remy-Jardin; J Mizon; A B Tonnel
Journal:  Am Rev Respir Dis       Date:  1993-06

8.  Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection.

Authors:  R I Lehrer; M J Cline
Journal:  J Clin Invest       Date:  1969-08       Impact factor: 14.808

9.  Defective candidacidal activity of alveolar macrophages and peripheral blood monocytes from patients with chronic obstructive pulmonary disease.

Authors:  A Vecchiarelli; M Dottorini; M Puliti; T Todisco; E Cenci; F Bistoni
Journal:  Am Rev Respir Dis       Date:  1991-05

Review 10.  Microorganisms and exacerbation of chronic obstructive pulmonary diseases: pathophysiological mechanisms.

Authors:  P Clementsen; K S Kristensen; S Norn
Journal:  Allergy       Date:  1992-06       Impact factor: 13.146

View more
  1 in total

1.  Effects of 3'-hydroxyfarrerol (IdB 1031), a novel flavonoid agent, on phagocyte products.

Authors:  F Meloni; P Ballabio; M Gorrini; M De Amici; C Marena; S Malandrino; M Luisetti
Journal:  Inflammation       Date:  1995-12       Impact factor: 4.092

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.